Allergy Asthma Immunol Res.  2016 Nov;8(6):527-534. 10.4168/aair.2016.8.6.527.

Burden of Respiratory Disease in Korea: An Observational Study on Allergic Rhinitis, Asthma, COPD, and Rhinosinusitis

• Yoo KH
• Ahn HR
• Park JK
• Kim JW
• Nam GH
• Hong SK
• Kim MJ
• Ghoshal AG
• Muttalif A
• Lin HC
• Thanaviratananich S
• Bagga S
• Faruqi R
• Sajjan S
• Baidya S
• Wang DY
• Cho SH

• KMID: 2349993
• DOI: http://doi.org/10.4168/aair.2016.8.6.527

Abstract

PURPOSE
The Asia-Pacific Burden of Respiratory Diseases (APBORD) study is a cross-sectional, observational one which has used a standard protocol to examine the disease and economic burden of allergic rhinitis (AR), asthma, chronic obstructive pulmonary disorder (COPD), and rhinosinusitis across the Asia-Pacific region. Here, we report on symptoms, healthcare resource use, work impairment, and associated costs in Korea.
METHODS
Consecutive participants aged ≥18 years with a primary diagnosis of asthma, AR, COPD, or rhinosinusitis were enrolled. Participants and their treating physician completed a survey detailing respiratory symptoms, healthcare resource use, and work productivity and activity impairment. Costs included direct medical cost and indirect cost associated with lost work productivity.
RESULTS
The study enrolled 999 patients. Patients were often diagnosed with multiple respiratory disorders (42.8%), with asthma/AR and AR/rhinosinusitis the most frequently diagnosed combinations. Cough or coughing up phlegm was the primary reason for the medical visit in patients with a primary diagnosis of asthma and COPD, whereas nasal symptoms (watery runny nose, blocked nose, and congestion) were the main reasons in those with AR and rhinosinusitis. The mean annual cost for patients with a respiratory disease was US$8,853 (SD 11,245) per patient. Lost productivity due to presenteeism was the biggest contributor to costs.
CONCLUSIONS
Respiratory disease has a significant impact on disease burden in Korea. Treatment strategies for preventing lost work productivity could greatly reduce the economic burden of respiratory disease.

Keyword

Respiratory tract disease; cost of illness; health care costs; Korea

MeSH Terms

Asthma*
Cost of Illness
Cough
Delivery of Health Care
Diagnosis
Efficiency
Health Care Costs
Humans
Korea*
Nose
Observational Study*
Presenteeism
Pulmonary Disease, Chronic Obstructive*
Respiratory Tract Diseases
Rhinitis, Allergic*

Figure

• 

  Fig. 1 Percentage of the enrolled patients (N=999) with a combination of diseases.

• 

  Fig. 2 Main reasons for medical visits and all current symptoms reported by primary diagnosis. COPD, chronic obstructive pulmonary disease.

• 

  Fig. 3 Percentage of patients with HCRU in the previous 4 weeks by primary diagnoses. Numbers above columns are the mean number of visits for patients that reported at least one visit. COPD, chronic obstructive pulmonary disease; GP, general practitioner/primary care physician.

• 

  Fig. 4 History of medication use for respiratory disease and medications prescribed at the medical visit by primary diagnoses. COPD, chronic obstructive pulmonary disease.

• 

  Fig. 5 Mean WPAI scores by primary diagnoses. COPD, chronic obstructive pulmonary disease; WPAI, work productivity and impairment.

• 

  Fig. 6 Annual direct and indirect costs for the study population by primary diagnoses. Work productivity costs calculated only for patients that reported impairment at work as a result of the disease. COPD, chronic obstructive pulmonary disease; GP, general practitioner/primary care physician.

Reference

1. World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. Geneva: World Health Organization;2007.

2. Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology. 2011; 16:659–665.

3. Song WJ, Kang MG, Chang YS, Cho SH. Epidemiology of adult asthma in Asia: toward a better understanding. Asia Pac Allergy. 2014; 4:75–85.

4. Rhee CS, Wee JH, Ahn JC, Lee WH, Tan KL, Ahn S, et al. Prevalence, risk factors and comorbidities of allergic rhinitis in South Korea: the Fifth Korea National Health and Nutrition Examination Survey. Am J Rhinol Allergy. 2014; 28:e107–e114.

5. Park HS, Choi GS, Cho JS, Kim YY. Epidemiology and current status of allergic rhinitis, asthma, and associated allergic diseases in Korea: ARIA Asia-Pacific workshop report. Asian Pac J Allergy Immunol. 2009; 27:167–171.

6. Kim YS, Kim NH, Seong SY, Kim KR, Lee GB, Kim KS. Prevalence and risk factors of chronic rhinosinusitis in Korea. Am J Rhinol Allergy. 2011; 25:117–121.

7. Lee YH, Yoon SJ, Kim EJ, Kim YA, Seo HY, Oh IH. Economic burden of asthma in Korea. Allergy Asthma Proc. 2011; 32:35–40.

8. Kim SY, Yoon SJ, Jo MW, Kim EJ, Kim HJ, Oh IH. Economic burden of allergic rhinitis in Korea. Am J Rhinol Allergy. 2010; 24:e110–e113.

9. Kim J, Rhee CK, Yoo KH, Kim YS, Lee SW, Park YB, et al. The health care burden of high grade chronic obstructive pulmonary disease in Korea: analysis of the Korean Health Insurance Review and Assessment Service data. Int J Chron Obstruct Pulmon Dis. 2013; 8:561–568.

10. Kim CY, Park HW, Ko SK, Chang SI, Moon HB, Kim YY, et al. The financial burden of asthma: a nationwide comprehensive survey conducted in the republic of Korea. Allergy Asthma Immunol Res. 2011; 3:34–38.

11. Kim C, Yoo KH, Rhee CK, Yoon HK, Kim YS, Lee SW, et al. Health care use and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea. Int J Tuberc Lung Dis. 2014; 18:737–743.

12. Wang DY, Ghoshal AG, Muttalif AR, Lin HC, Thanaviratananich S, Bagga S, et al. Quality of life and economic burden of respiratory disease in Asia-Pacific—Asia-Pacific Burden of Respiratory Diseases (APBORD) study. Value Health Reg Issues. 2016; 9:72–77.

13. Cho SH, Lin HC, Ghoshal A, Muttalif A, Thanaviratananich S, Bagga S, et al. Respiratory disease in the Asia-Pacific region: cough as a key symptom. Allergy Asthma Proc. 2016; 37:131–140.

14. World Health Organization. International statistical classification of diseases and related health problems. 10th rev. ed. Geneva: World Health Organization;2010.

15. Global Initiatives for Asthma. Global strategy for asthma management and prevention (2011 update). [place unknown]: Global Initiatives for Asthma;2011.

16. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. [place unknown]: Global Initiative for Chronic Obstructive Lung Disease;2010.

17. Fokkens W, Lund V, Mullol J. European Position Paper on Rhinosinusitis and Nasal Polyps group. European Position Paper on Rhinosinusitis and Nasal Polyps 2007. Rhinol Suppl. 2007; 1–136.

18. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2) LEN and AllerGen). Allergy. 2008; 63:Suppl 86. 8–160.

19. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993; 4:353–365.

20. Bousquet J, Gaugris S, Kocevar VS, Zhang Q, Yin DD, Polos PG, et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the improving asthma control trial. Clin Exp Allergy. 2005; 35:723–727.

21. Berrettini S, Carabelli A, Sellari-Franceschini S, Bruschini L, Abruzzese A, Quartieri F, et al. Perennial allergic rhinitis and chronic sinusitis: correlation with rhinologic risk factors. Allergy. 1999; 54:242–248.

22. Kim MH, Jung JW, Cho SH, Min KU, Kang HR. The impact of sinusitis on the long-term clinical outcomes of asthma. Asia Pac Allergy. 2014; 4:222–229.

23. Reilly MC, Tanner A, Meltzer EO. Work, classroom and activity impairment instruments: validation studies in allergic rhinitis. Clin Drug Investig. 1996; 11:278–288.

24. Fletcher MJ, Upton J, Taylor-Fishwick J, Buist SA, Jenkins C, Hutton J, et al. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health. 2011; 11:612.

25. Demoly P, Gueron B, Annunziata K, Adamek L, Walters RD. Update on asthma control in five European countries: results of a 2008 survey. Eur Respir Rev. 2010; 19:150–157.

26. Allergies in Asia-Pacific. Allergies in Asia-Pacific™: a landmark survey of nasal allergy sufferers: findings for Korea [Internet]. Seoul: Allergies in Asia-Pacific;2014. cited 2015 Jan 7. Available from: http://www.allergiesinasiapacific.com./pdfs/Korea_FINAL%20100603.pdf.

27. Wouters EF. Economic analysis of the confronting COPD survey: an overview of results. Respir Med. 2003; 97:Suppl C. S3–S14.

28. Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009; 9:24.